Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673192 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| Carbon Dioxide SCHEMBL30932543 | 0.93 | KDM4E (0.86) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| Benzoquinone SCHEMBL30677004 | 0.90 | KDM4E (0.81) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29126970 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL31251989 | 0.79 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29229082 | 0.78 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL31612336 | 0.77 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29229124 | 0.77 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL30932617 | 0.77 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL31612371 | 0.77 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108948025-A | A kind of preparation method of pyrrolo- [1,2-a] quinoxaline compounds of novel spiral cyclisation | 兰州大学 | 2018-12-07 | — | — | CN | claimed |
| CN-108409743-A | A kind of preparation method of pyrrolo- [1,2-a] quinoxaline compounds of alkyl nitrile substitution | 兰州大学 | 2018-08-17 | — | — | CN | claimed |
| CN-104995191-A | Tricyclic quinoline and quinoxaline derivatives | ABBVIE DEUTSCHLAND | 2015-10-21 | — | — | CN | claimed |
| CN-104418862-A | Tricyclic chinoline and quinoxaline derivatives | AbbVie Deutschland GmbH and Co KG | 2015-03-18 | — | — | CN | claimed |
| EP-1539168-A2 | TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO(3,4-D)PYRIDAZINE COMPOUNDS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004006836-A2 | TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO[3,4-D]PYRIDAZINE COMPOUNDS | MERCK & CO., INC. (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090127-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | REVOLUTION MEDICINES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4704850-A1 | COMBINATION THERAPY FOR A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4687905-A1 | COMPOSITIONS FOR INDUCING RAS GTP HYDROLYSIS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-0636625-A2 | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-02-01 | — | — | EP | disclosed |
| US-4163745-A | ANTIDIABETIC, HYPOGLYCEMIC | PFIZER INC. (US) | 1979-08-07 | — | — | US | disclosed |
| US-4141898-A | Imidazo pyridinium quaternary salts as hypoglycemic agents | PFIZER INC. (US) | 1979-02-27 | — | — | US | disclosed |
| US-4129567-A | IMIDAZOPYRIDINES AND ISOB IDINE | PFIZER INC. (US) | 1978-12-12 | — | — | US | disclosed |
| US-4093616-A | PYRROLO(1,2-A)PYRAZINIUM, PYRAZOLO(1,5-A)PYRIDINIUM, 1H-IMIDAZO(2,1-A)ISOQUINOLINIUM, OR IMIDAZO(5,1-A)ISOQUINOLINIUM SALTS | PFIZER INC. (US) | 1978-06-06 | — | — | US | disclosed |
| US-4044015-A | Imidazopyridinium compounds as hypoglycemic agents | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-3939159-A | ANTICONVULSANT, CNS DEPRESSANT | AMERICAN HOECHST CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | KRAS, NRAS, RAB1A | KDM4E 1759/4885ALDH1A1 4312/4885HPGD 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.